home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Akero Therapeutics, Inc. - Common Stock (NQ:AKRO)

54.74 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akero Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

March 04, 2024

Via Benzinga

Akero Therapeutics' Stock Is Soaring Monday - Here's Why ↗

March 04, 2024

Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, marking a major milestone in liver disease treatment.

Via Benzinga

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment ↗

March 04, 2024

Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing.

Via Investor's Business Daily

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

March 04, 2024

We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning!

Via InvestorPlace

Akero Therapeutics: Q4 Earnings Insights ↗

February 29, 2024

Via Benzinga

11 Analysts Have This to Say About Akero Therapeutics ↗

November 14, 2023

Via Benzinga

Akero Therapeutics: Q3 Earnings Insights ↗

November 13, 2023

Via Benzinga

Why Akero Therapeutics Shares Are Slumping This Week ↗

October 12, 2023

Akero's lead therapy fell short of its goals in a phase 2b trial to treat NASH.

Via The Motley Fool

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

March 04, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Super Micro Computer, Deckers Outdoor And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

March 04, 2024

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) rose sharply in today’s pre-market...

Via Benzinga

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

February 29, 2024

Investor webcast on Monday, March 4 at 8:00 a.m. ET to present clinical data

From Akero Therapeutics Inc.

Via GlobeNewswire

Analyst Ratings for Akero Therapeutics ↗

October 11, 2023

Via Benzinga

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 29, 2024

From Akero Therapeutics Inc.

Via GlobeNewswire

Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena ↗

February 26, 2024

The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost.

Via Investor's Business Daily

Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday ↗

February 23, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 100 points on Friday.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 06, 2024

Via Benzinga

Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 23, 2024

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.

Via Benzinga

Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Akero Therapeutics

Via GlobeNewswire

Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program

December 18, 2023

From Akero Therapeutics

Via GlobeNewswire

Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

From Akero Therapeutics

Via GlobeNewswire

Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023

November 10, 2023

From Akero Therapeutics

Via GlobeNewswire

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

November 08, 2023

From Akero Therapeutics

Via GlobeNewswire

Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference

October 17, 2023

From Akero Therapeutics

Via GlobeNewswire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

October 13, 2023

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance...

Via Benzinga

E2open, Sharecare And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 12, 2023

U.S. stock futures traded higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward ↗

October 11, 2023

Tuesday, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 11, 2023

Via Benzinga

Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 11, 2023

Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares jumped 1067% to $2.80 after the company released new data demonstrating superiority of TPST-1120 arm across multiple study endpoints in...

Via Benzinga

Wegovy Maker Novo Nordisk, Akero Therapeutics, Eli Lilly, Athena Consumer Acquisition, Tesla: Why These 5 Stocks Are Trending Today ↗

October 10, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 130 points on Tuesday.

Via Benzinga

Topics Stocks

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com